Cardio Diagnostics
Get Started

Our Solutions

Cardiovascular Disease is the Leading Cause of Death in the U.S.

Cardiovascular disease (CVD) is responsible for nearly 1 in 3 deaths in the U.S. It claims more lives in the U.S. than all forms of cancer and accidental deaths combined.

CVD is not a single illness. It is a family of diseases that affect the heart and blood vessels, including coronary heart disease (CHD), stroke, heart failure and peripheral artery disease.

Cardiovascular Disease

80-90% of cardiovascular disease is estimated to be preventable through early detection and proactive management.,,

Explore Our Solutions

Coronary Heart Disease is the Most Common Type of Cardiovascular Disease

CHD often develops silently over many years, and its first symptom may be a heart attack.

#2

cause of hospitalization and adds $13,000 more per year to patient healthcare costs,

1 in 20

U.S. adults aged over 20 years live with coronary heart disease

3-4 million

Americans are affected by Ischemia with No Obstructive Coronary Arteries (INOCA), a subset of CHD

For Many, a Heart Attack is the First Sign of Coronary Heart Disease

Heart attacks don't always announce themselves. Many occur without chest pain, especially in women and people with diabetes.

40 seconds

is how often someone in the U.S. experiences a heart attack

1 in 5

heart attacks are silent, occurring without warning

800,000+

is the number of heart attacks occurring annually

Waiting on Traditional Risk Factors and Obvious Symptoms to Develop Can Create Blind Spots

50%

of those with CHD do not have traditional risk factors

30-65%

of suspected ischemia cases reveal no obstructive disease

39%

is the average sensitivity of conventional risk calculators

Traditional Methods Fall Short in Personalizing Cardiovascular Care, Leaving Risk Underestimated and Disease Missed Altogether

Cardio Diagnostics' Solutions Redefine Prevention and Care by Leveraging Each Patient's Unique Molecular Biology

Our clinical solutions can reveal what traditional methods may miss by assessing a patient's epigenetic and genetic biomarkers. For non-clinical stakeholders, our population-level insights and biopharma research platform turn complex epigenetic and genetic data into clear, actionable insights.

Clinical Solutions

Epi+Gen CHD™

Three-year Coronary Heart Disease Event Risk Assessment

Rx Only   FSA/HSA Eligible

Learn More
PrecisionCHD™

Coronary Heart Disease Detection and Management

Rx Only   FSA/HSA Eligible

Learn More

Population Health and Biopharma Solutions

HeartRisk™

Real-Time Population Insights Platform

Uncover population cardiovascular risk profile in real-time. Identify opportunities to reduce healthcare spend.

Learn More
CardioInnovate™

BioPharma Research Platform

Discover new cardiovascular biomarkers with AI and epigenetics. Design smarter, more precise clinical trials.

Learn More

Explore Tailored Resources Designed for
Patients, Providers, and Employers

Patients

Take the first step today toward better heart health.

Request a Test
Patient

Providers

Advance prevention and detection of coronary heart disease with precision medicine insights.

Integrate Testing Into Your Practice
Provider

Employers

Protect your workforce and lower healthcare spend.

Offer Testing to Your Employees
Employer
  1. CDC. Heart Disease Facts. cdc.gov/heart-disease
  2. AHA. Heart disease remains leading cause of death as key health risk factors continue to rise. heart.org/news/heart-disease-remains-leading-cause-of-death-as-key-health-risk-factors-continue-to-rise
  3. World Heart Federation. Prevention. World Heart Federation website. Updated 2023. Accessed September 17, 2025. world-heart-federation.org/prevention
  4. Cleveland Clinic. 90 Percent of Heart Disease Is Preventable Through Healthier Diet, Regular Exercise and Not Smoking. Cleveland Clinic Newsroom. Published September 29, 2021. Accessed September 17, 2025. clevelandclinic.org/newsroom
  5. European Heart Network. Cardiovascular Disease Risk Assessment Programmes. January 2021. Accessed September 17, 2025. ehnheart.org/cvd-risk-assessment
  6. Haidar, A., Gajjar, A., Parikh, R. V., Benharash, P., Fonarow, G. C., Watson, K., Needleman, J., & Ziaeian, B. (2025). National Costs for Cardiovascular-Related Hospitalizations and Inpatient Procedures in the United States, 2016 to 2021. The American Journal of Cardiology, 234, 63–70.https://doi.org/10.1016/j.amjcard.2024.10.003
  7. Kazi, D. S., Elkind, M. S. V., Deutsch, A., Dowd, W. N., Heidenreich, P., Khavjou, O., Mark, D., Mussolino, M. E., Ovbiagele, B., Patel, S. S., Poudel, R., Weittenhiller, B., Powell-Wiley, T. M., & Joynt, K. E. (2024). Forecasting the Economic Burden of Cardiovascular Disease and Stroke in the United States Through 2050: A Presidential Advisory From the American Heart Association. Circulation, 150(4).https://doi.org/10.1161/cir.0000000000001258
  8. Polyak, A., Wei, J., Gulati, M., & Bairey Merz, N. (2024). Clinical aspects of ischemia with no obstructive coronary artery disease (INOCA). American Heart Journal Plus, 37, 100352.https://doi.org/10.1016/j.ahjo.2023.100352
  9. Cardio Diagnostics, Inc. Internal Claims Data Analysis.
  10. Bastiany, A., Pacheco, C., Sedlak, T., Saw, J., Miner, S. E. S., Liu, S., Lavoie, A., Kim, D. H., Gulati, M., & Graham, M. M. (2022). A practical approach to invasive testing in ischemia with no obstructive coronary arteries (INOCA). CJC Open, 4(8), 709-720.https://doi.org/10.1016/j.cjco.2022.04.009
  11. Dogan MV, Knight S, Dogan TK, Knowlton KU, Philibert R. External validation of integrated genetic-epigenetic biomarkers for predicting incident coronary heart disease.Epigenomics. 2021;13(14):1137-1152. doi:10.2217/epi-2021-0123